Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients

Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients

Background: Nirmatrelvir/Ritonavir has been shown to reduce the risk of COVID-19 progression by 88% compared to placebo, while Molnupiravir reduced it by 31%. However, these two agents have not been compared head-to-head. We therefore compared the safety and efficacy of both agents for the treatment...

Full description

Bibliographic Details
Main Authors: Andrea J. Haddad, Ray Y. Hachem, Mohamed Moussa, Ying Jiang, Hiba R. Dagher, Patrick Chaftari, Anne-Marie Chaftari, Issam I. Raad
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
COVID-19
coronaviruses
SARS-CoV-2
cancer
immunocompromised
therapy
Online Access:https://www.mdpi.com/2072-6694/16/5/1055

Internet

https://www.mdpi.com/2072-6694/16/5/1055

Similar Items